ProText Mobility, Inc. (TXTM)
USD 0.0
(-11.11%)
USD 0.0
(-11.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 52.64 Thousand USD | -12.45% |
| 2022 | 60.12 Thousand USD | -30.08% |
| 2021 | 86 Thousand USD | 4.88% |
| 2020 | 82 Thousand USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 321.49 Thousand USD | -35.65% |
| 2017 | 499.57 Thousand USD | 72.03% |
| 2016 | 290.4 Thousand USD | 0.0% |
| 2013 | 927.94 Thousand USD | -31.1% |
| 2012 | 1.34 Million USD | -49.97% |
| 2011 | 2.69 Million USD | -36.93% |
| 2010 | 4.26 Million USD | 10.2% |
| 2009 | 3.87 Million USD | 7.1% |
| 2008 | 3.61 Million USD | -1.83% |
| 2007 | 3.68 Million USD | 7.57% |
| 2006 | 3.42 Million USD | -6.09% |
| 2005 | 3.64 Million USD | 227.85% |
| 2004 | 1.11 Million USD | 31.95% |
| 2003 | 842.86 Thousand USD | 120.09% |
| 2002 | 382.97 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4530.00 USD | -76.66% |
| 2024 Q1 | 19.4 Thousand USD | 265.89% |
| 2023 Q3 | 6418.00 USD | -75.03% |
| 2023 Q4 | 5304.00 USD | -17.36% |
| 2023 FY | 52.64 Thousand USD | -12.45% |
| 2023 Q1 | 15.22 Thousand USD | 121.12% |
| 2023 Q2 | 25.69 Thousand USD | 68.8% |
| 2022 Q2 | 25 Thousand USD | 13.64% |
| 2022 FY | 60.12 Thousand USD | -30.08% |
| 2022 Q1 | 22 Thousand USD | 0.0% |
| 2022 Q3 | 6742.00 USD | -73.03% |
| 2022 Q4 | 6885.00 USD | 2.12% |
| 2021 Q3 | 24 Thousand USD | 20.0% |
| 2021 Q1 | 20 Thousand USD | 0.0% |
| 2021 FY | 86 Thousand USD | 4.88% |
| 2021 Q2 | 20 Thousand USD | 0.0% |
| 2021 Q4 | 22 Thousand USD | -8.33% |
| 2020 FY | 82 Thousand USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2018 FY | 321.49 Thousand USD | -35.65% |
| 2017 FY | 499.57 Thousand USD | 72.03% |
| 2016 FY | 290.4 Thousand USD | 0.0% |
| 2014 Q1 | 220.39 Thousand USD | -26.41% |
| 2014 Q3 | 261.8 Thousand USD | 5.3% |
| 2014 Q2 | 248.62 Thousand USD | 12.81% |
| 2013 Q1 | 195 Thousand USD | -37.74% |
| 2013 FY | 927.94 Thousand USD | -31.1% |
| 2013 Q4 | 299.48 Thousand USD | 23.65% |
| 2013 Q2 | 191.26 Thousand USD | -1.92% |
| 2013 Q3 | 242.19 Thousand USD | 26.63% |
| 2012 Q1 | 371.5 Thousand USD | -52.94% |
| 2012 Q3 | 302.82 Thousand USD | -15.7% |
| 2012 FY | 1.34 Million USD | -49.97% |
| 2012 Q4 | 313.21 Thousand USD | 3.43% |
| 2012 Q2 | 359.23 Thousand USD | -3.3% |
| 2011 Q1 | 794.57 Thousand USD | -41.11% |
| 2011 Q2 | 533.58 Thousand USD | -32.85% |
| 2011 Q3 | 574.21 Thousand USD | 7.61% |
| 2011 Q4 | 789.47 Thousand USD | 37.49% |
| 2011 FY | 2.69 Million USD | -36.93% |
| 2010 Q2 | 1.14 Million USD | 23.57% |
| 2010 FY | 4.26 Million USD | 10.2% |
| 2010 Q4 | 1.34 Million USD | 59.24% |
| 2010 Q3 | 847.34 Thousand USD | -25.97% |
| 2010 Q1 | 926.32 Thousand USD | 41.37% |
| 2009 Q4 | 655.23 Thousand USD | -54.74% |
| 2009 FY | 3.87 Million USD | 7.1% |
| 2009 Q1 | 1.02 Million USD | -68.46% |
| 2009 Q2 | 749.67 Thousand USD | -26.51% |
| 2009 Q3 | 1.44 Million USD | 93.13% |
| 2008 FY | 3.61 Million USD | -1.83% |
| 2008 Q4 | 3.23 Million USD | 46.54% |
| 2008 Q3 | 2.2 Million USD | 109.88% |
| 2008 Q2 | 1.05 Million USD | 36.05% |
| 2008 Q1 | 772.81 Thousand USD | -0.43% |
| 2007 Q4 | 776.17 Thousand USD | -14.67% |
| 2007 FY | 3.68 Million USD | 7.57% |
| 2007 Q2 | 1.02 Million USD | 5.26% |
| 2007 Q1 | 973.26 Thousand USD | 5.5% |
| 2007 Q3 | 909.66 Thousand USD | -11.21% |
| 2006 Q3 | 795.32 Thousand USD | -5.18% |
| 2006 FY | 3.42 Million USD | -6.09% |
| 2006 Q2 | 838.74 Thousand USD | 12.51% |
| 2006 Q1 | 745.46 Thousand USD | -70.22% |
| 2006 Q4 | 922.55 Thousand USD | 16.0% |
| 2005 Q2 | 359.99 Thousand USD | 31.42% |
| 2005 FY | 3.64 Million USD | 227.85% |
| 2005 Q1 | 273.93 Thousand USD | 3.89% |
| 2005 Q3 | 495.57 Thousand USD | 37.66% |
| 2005 Q4 | 2.5 Million USD | 405.16% |
| 2004 FY | 1.11 Million USD | 31.95% |
| 2004 Q2 | 293.56 Thousand USD | -0.02% |
| 2004 Q3 | 261.28 Thousand USD | -10.99% |
| 2004 Q1 | 293.62 Thousand USD | -38.18% |
| 2004 Q4 | 263.68 Thousand USD | 0.92% |
| 2003 Q1 | 136.6 Thousand USD | 0.0% |
| 2003 FY | 842.86 Thousand USD | 120.09% |
| 2003 Q4 | 474.96 Thousand USD | 419.07% |
| 2003 Q3 | 91.5 Thousand USD | -34.54% |
| 2003 Q2 | 139.78 Thousand USD | 2.33% |
| 2002 FY | 382.97 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 96.058% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 98.956% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.822% |
| Nascent Biotech, Inc. | 2.22 Million USD | 97.639% |
| Rebus Holdings, Inc. | 664 Thousand USD | 92.072% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.859% |
| Qrons Inc. | 643.67 Thousand USD | 91.822% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 86.487% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.908% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 87.33% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.611% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.939% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 98.93% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 79.887% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.939% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 98.195% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 96.495% |
| Mesoblast Limited | 5.9 Million USD | 99.108% |
| Marizyme, Inc. | 19.23 Million USD | 99.726% |
| Genus plc | 147.7 Million USD | 99.964% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.4% |
| Pharming Group N.V. | 225.49 Million USD | 99.977% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 97.43% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 96.076% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.369% |
| ContraFect Corporation | 56.88 Million USD | 99.907% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 98.806% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 96.44% |
| IMV Inc. | 37.7 Million USD | 99.86% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 98.113% |
| MultiCell Technologies, Inc. | 567.42 USD | -9177.431% |
| ONE Bio Corp. | 6.44 Million USD | 99.183% |
| Accustem Sciences Inc. | 3.74 Million USD | 98.595% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.939% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 90.104% |
| Q BioMed Inc. | 3.43 Million USD | 98.468% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.787% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 97.997% |
| Biomind Labs Inc. | 994.18 Thousand USD | 94.705% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.947% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 97.008% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 99.216% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 97.176% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 310.568% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.671% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 97.131% |
| GB Sciences, Inc. | 1.42 Million USD | 96.294% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.458% |
| HST Global, Inc. | 140.9 Thousand USD | 62.641% |
| CSL Limited | 3.44 Billion USD | 99.998% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 95.32% |
| Halberd Corporation | 74.84 Thousand USD | 29.662% |
| Enzolytics Inc. | 2.17 Million USD | 97.585% |
| Agentix Corp. | 1.37 Million USD | 96.162% |
| Resverlogix Corp. | 12.71 Million USD | 99.586% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 98.558% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.997% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 94.958% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 97.811% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 96.667% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 98.454% |
| AVAX Technologies, Inc. | 7.31 Million USD | 99.28% |
| Zenith Capital Corp. | 8.94 Million USD | 99.411% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.994% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -202.176% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 97.856% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 69.307% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 97.26% |
| Kadimastem Ltd | 2.41 Million USD | 97.816% |
| Helix BioMedix, Inc. | 1.97 Million USD | 97.331% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.516% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.771% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 70.994% |
| LadRx Corporation | 3.81 Million USD | 98.619% |
| Cell Source, Inc. | 4.32 Million USD | 98.783% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 94.3% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 94.3% |
| NovAccess Global Inc. | 2.46 Million USD | 97.866% |
| Affymax, Inc. | 39.38 Million USD | 99.866% |
| Itoco Inc. | 919.14 Thousand USD | 94.273% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 98.758% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 95.296% |
| Mobile Lads Corp. | 554.54 Thousand USD | 90.507% |
| CytoDyn Inc. | 18.05 Million USD | 99.708% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -109.154% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 76.08% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 96.292% |
| SYBLEU INC | 160.87 Thousand USD | 67.278% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 97.102% |
| International Stem Cell Corporation | 5.27 Million USD | 99.001% |
| Bioxytran, Inc. | 3.82 Million USD | 98.622% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -158.772% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.855% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 96.746% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 92.846% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 98.308% |
| Neutra Corp. | 243.82 Thousand USD | 78.41% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.698% |
| PureTech Health plc | 144.59 Million USD | 99.964% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.743% |
| IXICO plc | 4.7 Million USD | 98.882% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.402% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.955% |
| CSL Limited | 3.89 Billion USD | 99.999% |
| Cellectis S.A. | 97.32 Million USD | 99.946% |